AV-353 (Anti-Notch 3 mAb)
AV-353 is the Company’s potent, selective, high affinity inhibitory antibody specific to Notch 3. The Notch 3 signaling pathway is important in cell-to-cell communication involving gene regulation mechanisms that control multiple cell differentiation processes during the entire life cycle. Scientific literature has implicated the Notch 3 receptor pathway in multiple diseases, including cancer, cardiovascular diseases and neurodegenerative conditions. AV-353 is being studied by AVEO’s collaborators at the Mayo Clinic in preclinical studies of triple negative breast cancer.
AV-353 is an investigational drug and has not yet been approved by the FDA.